Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Identifier
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancer immunology immunotherapy. 71. -. 2022. 1975. 1988. -
- Ereignis
-
Veröffentlichung
- (wo)
-
Mainz
- (wer)
-
Universitätsbibliothek der Johannes Gutenberg-Universität Mainz
- (wann)
-
2022
- Urheber
-
Salomon, Nadja
Selmi, Abderaouf
Grunwitz, Christian
Kong, Anthony
Stanganello, Eliana
Neumaier, Jennifer
Petschenka, Jutta
Diken, Mustafa
Kreiter, Sebastian
Türeci, Özlem
Sahin, Ugur
Vascotto, Fulvia
- DOI
-
10.25358/openscience-7649
- Handle
- URN
-
urn:nbn:de:101:1-2022090102234610756922
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
07.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Salomon, Nadja
- Selmi, Abderaouf
- Grunwitz, Christian
- Kong, Anthony
- Stanganello, Eliana
- Neumaier, Jennifer
- Petschenka, Jutta
- Diken, Mustafa
- Kreiter, Sebastian
- Türeci, Özlem
- Sahin, Ugur
- Vascotto, Fulvia
- Universitätsbibliothek der Johannes Gutenberg-Universität Mainz
Entstanden
- 2022
Ähnliche Objekte (12)
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Preclinical investigation of DNA immunization with a rearranged human papillomavirus type 16 (HPV16) E7 oncogene
MPS1 is involved in the HPV16-E7-mediated centrosomes amplification
HPV16 mutant E6/E7 construct is protective in mouse model
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors
Modulation der Immunogenität von HPV16-, L1-E7-chimären Virus-ähnlichen Partikeln
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model
Evaluation of HPV16 E7 expression in head and neck carcinoma cell lines and clinical specimens
Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein
Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Preclinical investigation of DNA immunization with a rearranged human papillomavirus type 16 (HPV16) E7 oncogene
MPS1 is involved in the HPV16-E7-mediated centrosomes amplification
HPV16 mutant E6/E7 construct is protective in mouse model
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors
Modulation der Immunogenität von HPV16-, L1-E7-chimären Virus-ähnlichen Partikeln
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model
Evaluation of HPV16 E7 expression in head and neck carcinoma cell lines and clinical specimens
Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein
Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Preclinical investigation of DNA immunization with a rearranged human papillomavirus type 16 (HPV16) E7 oncogene
MPS1 is involved in the HPV16-E7-mediated centrosomes amplification
HPV16 mutant E6/E7 construct is protective in mouse model
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors
Modulation der Immunogenität von HPV16-, L1-E7-chimären Virus-ähnlichen Partikeln
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model
Evaluation of HPV16 E7 expression in head and neck carcinoma cell lines and clinical specimens
Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein